Citadel Advisors
BIOA

Citadel Advisors’s BioAge Labs BIOA Stock Holding History

Citadel Advisors’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$681K Buy
+27,800
New +$502K ﹤0.01% 9147
2025
Q4 		– Sell
-11,100
Closed -$65.3K – 14362
2025
Q3 		$65.3K Buy
+11,100
New +$52K ﹤0.01% 12068

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Citadel Advisors's BIOA Position: Q2 2026 in Review

Citadel Advisors opened a new position in BioAge Labs (BIOA) in Q2 2026: 78,365 shares worth $1.92M. The stake represents ﹤0.01% of the portfolio and ranks #6639 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in BIOA as recently as Q4 2025.

Citadel Advisors first reported a position in BIOA in Q3 2024 and has held it in 5 quarters since. The position peaked at $4.45M in Q3 2024. 151 funds tracked by Wall St. Rank hold BIOA as of Q2 2026.

  • Citadel Advisors held 78,365 shares of BioAge Labs worth $1.92M as of Q2 2026.
  • BioAge Labs was a new Citadel Advisors position in Q2 2026.
  • BioAge Labs made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #6639 holding.
  • Citadel Advisors first reported a position in BioAge Labs in Q3 2024 and has held it in 5 quarters since.
  • Citadel Advisors's BioAge Labs position peaked at $4.45M in Q3 2024.
  • 151 funds tracked by Wall St. Rank held BioAge Labs as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.